Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37306554)

  • 1. Keeping It in the Family: HER3 as a Target in Brain Metastases.
    Kabraji S; Lin NU
    Clin Cancer Res; 2023 Aug; 29(16):2961-2963. PubMed ID: 37306554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.
    Tomasich E; Steindl A; Paiato C; Hatziioannou T; Kleinberger M; Berchtold L; Puhr R; Hainfellner JA; Müllauer L; Widhalm G; Eckert F; Bartsch R; Heller G; Preusser M; Berghoff AS
    Clin Cancer Res; 2023 Aug; 29(16):3225-3236. PubMed ID: 37036472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
    Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
    Kodack DP; Askoxylakis V; Ferraro GB; Sheng Q; Badeaux M; Goel S; Qi X; Shankaraiah R; Cao ZA; Ramjiawan RR; Bezwada D; Patel B; Song Y; Costa C; Naxerova K; Wong CSF; Kloepper J; Das R; Tam A; Tanboon J; Duda DG; Miller CR; Siegel MB; Anders CK; Sanders M; Estrada MV; Schlegel R; Arteaga CL; Brachtel E; Huang A; Fukumura D; Engelman JA; Jain RK
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
    Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
    Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
    Drago JZ; Ferraro E; Abuhadra N; Modi S
    Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer.
    Wang A; Zhang H; Wang J; Zhang S; Xu Z
    Aging (Albany NY); 2020 Mar; 12(6):4866-4878. PubMed ID: 32170048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.
    Improta G; Zupa A; Fillmore H; Deng J; Aieta M; Musto P; Liotta LA; Broaddus W; Petricoin EF; Wulfkuhle JD
    J Proteome Res; 2011 Jul; 10(7):3089-97. PubMed ID: 21574647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
    Salameh A; Fan X; Choi BK; Zhang S; Zhang N; An Z
    Oncotarget; 2017 Jan; 8(4):6526-6539. PubMed ID: 28036286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.